Cologne, Germany

Andreas Wilmen

This inventor holds 17 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft, Aronora Inc.. Active years: 2012-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Wilmen. Retrieved from https://idiyas.com/inventor/andreas-wilmen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 58.8

 

 

Average Co-Inventor Count = 7.9

ph-index = 5

Forward Citations = 57(Granted Patents)


Location History:

  • Köln, DE (2012 - 2020)
  • Cologne, DE (2017 - 2021)

Company Filing History:


Years Active: 2012-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Monoclonal Antibodies
Coagulation Factor XI
Activated Protein C
Therapeutic Use
Neutralizing Antibodies
Nucleic Acids
Host Cells
Imidazopyrimidines
GSK3 Inhibitors
Relaxin Fusion Polypeptides
Pyrazolopyrazines
Triazolopyrimidines
17 patents (USPTO):Explore Patents

Title: Innovator in Antibody Development - Andreas Wilmen

Introduction

Andreas Wilmen, an accomplished inventor based in Köln, Germany, has made significant contributions to the field of biotechnology with a remarkable portfolio of 17 patents. His innovative work primarily focuses on the development of humanized monoclonal antibodies that address critical challenges in coagulation and thrombosis.

Latest Patents

One of his most recent patents is titled "Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof." This invention provides optimized humanized antibodies that selectively bind to and inhibit activated protein C without affecting its unactivated counterpart. The antibodies specifically target distinct epitopes beyond the catalytic triad of human activated protein C, offering promising treatment methods.

Another notable patent from Andreas Wilmen is centered around "Antibodies capable of binding to the coagulation factor XIa and uses thereof." This invention focuses on creating antibodies that can bind to coagulation factor XI and its activated form, factor XIa. The methods of using these antibodies aim to inhibit platelet aggregation, which is crucial in preventing thrombus formation.

Career Highlights

Andreas has worked with prominent organizations, including Bayer Intellectual Property GmbH and Bayer Pharma Aktiengesellschaft. His expertise in the field has contributed to advancements in therapeutic applications of monoclonal antibodies.

Collaborations

Throughout his career, he has collaborated with notable colleagues such as Christoph Freiberg and Stephan Siegel. These partnerships have fostered innovation and research in antibody development, enhancing the potential impact of their inventions.

Conclusion

Andreas Wilmen's work exemplifies the intersection of innovative thinking and practical applications in biotechnology. His significant contributions continue to pave the way for advancements in medical treatment, particularly in the realm of coagulation disorders. With his impressive portfolio of patents, he remains a key figure in the research and development of monoclonal antibodies, driving progress in the healthcare sector.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…